Melanoma/skin cancer 2022: ‘Transformative’ advances and new insights into adverse events

Source: Healio, December 2022

Several novel treatment regimens for melanoma/skin cancer emerged during the past year.

These include a cell therapy that induced response in one-third of patients with advanced unresectable or metastatic melanoma, as well as a neoadjuvant therapy that induced response in more than half of patients with resectable cutaneous squamous cell carcinoma.

Other research provided new insights into the potential for major adverse cardiac events after immune checkpoint inhibitor-based therapy.
READ THE ORIGINAL FULL ARTICLE